한국어
English
日本語
中文(简体)
Zykadia Capsule 150 mg (Ceritinib)
150mg
Hard capsule · Prescription medication
Korea Novartis Co., Ltd.
Ceritinib is an anti-cancer drug component used in the treatment of non-small cell lung cancer.
MFDS ingredient code M261400
Ceritinib belongs to the class of anti-cancer agents known as ALK (anaplastic lymphoma kinase) inhibitors. It is primarily used for the treatment of non-small cell lung cancer patients with ALK gene mutations. It is included in the medication to inhibit the growth of cancer cells.
Ceritinib blocks the activity of the ALK protein inside cancer cells, preventing the signaling for cancer cell proliferation. As a result, the growth of cancer cells is inhibited and the tumor size decreases. It also shows effectiveness against certain brain metastases.
Approved uses differ by product. Check each product's information for its actual use.
Ceritinib has superior brain penetration compared to other ALK inhibitors, making it effective for patients with brain metastases. Furthermore, it has a differentiated mechanism of action when resistance occurs compared to other ALK inhibitors. Its side effect profile is also somewhat different.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.